So the phase 1 is showing surprising efficacy results even in some unexpected cancers, so as the expansion progresses and if we see continued and improving results in patients does this bring the large pharmas into play. The big Irish Pharma buy out of a small bio company some months ago ( commented on twitter by SPL CEO ) had a comment in the write up that results for one particular patient was what sparked the pharma into putting forward a buyout offer ( don't know how true that was but it was mentioned). Do we see interest from the big boys for Starpharma DEP DOX if the results of the expansion impress. Appreciate any considered opinions.
SPL Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
